New insider activity at NewAmsterdam Pharma Company ( (NAMS) ) has taken place on September 5, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CAO Kooij Louise Frederika recently sold 18,073 shares of NewAmsterdam Pharma Company stock, amounting to a total transaction value of $453,451.
Recent Updates on NAMS stock
NewAmsterdam Pharma Company has recently seen significant developments that have influenced its stock ratings and price targets. The company released an updated corporate investor presentation on September 2, 2025, highlighting progress in clinical trials for its LDL-C lowering treatment, obicetrapib, and strategic plans for a U.S. commercial launch. This has led to a positive outlook from analysts, with Wells Fargo initiating coverage with an Overweight rating, citing the multibillion-dollar potential of CETP inhibition. Additionally, the European Medicines Agency validated the Marketing Authorization Application for obicetrapib, marking a crucial step forward in its European market strategy. Despite these advancements, the stock’s overall rating remains neutral due to financial performance challenges and valuation concerns, including lack of profitability and negative cash flows, which offset the strong technical momentum and positive corporate events.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
NewAmsterdam Pharma’s overall score is driven by strong corporate events and technical analysis, offset by financial performance challenges and high-risk valuation. The company’s strategic progress in clinical trials and regulatory achievements are promising, but profitability remains a key concern.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
YTD Price Performance: -1.16%
Average Trading Volume: 881,684
Technical Sentiment Signal: Buy
Current Market Cap: $2.89B